Tetraphase Pharmaceuticals Inc. (TTPH)

1.42
NASDAQ : Health Technology
Prev Close 1.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.01 / 6.63
Avg Volume 637.90K
Exchange NASDAQ
Shares Outstanding 53.63M
Market Cap 74.00M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tetraphase Pharmaceuticals Presents Detailed Results From Phase 3 Trials Of Eravacycline At 25th European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

Tetraphase Pharmaceuticals Presents Detailed Results From Phase 3 Trials Of Eravacycline At 25th European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)

Late Breaker and Oral Presentations Support Eravacycline's Potential as a New IV/Oral Antibiotic Treatment for Multidrug-Resistant Infections

First Week of TTPH August 21st Options Trading

First Week of TTPH August 21st Options Trading

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the August 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 143 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

'Mad Money' Lightning Round: We're Staying Away From Adobe

'Mad Money' Lightning Round: We're Staying Away From Adobe

Cramer says to buy Berkshire Hathaway and wait on Rocket Fuel.

Tetraphase Pharmaceuticals Reports Fourth-Quarter And Full-Year 2014 Financial Results

Tetraphase Pharmaceuticals Reports Fourth-Quarter And Full-Year 2014 Financial Results

Company to Host Conference Call at 4:30 p.m. ET Today

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

When to take profits is a tricky but important decision.

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Fibrocell Science and Prothena have several 'shots on goal.'

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Tetraphase Pharmaceuticals (TTPH) Hits New Lifetime High

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Perilous Reversal Stock: Tetraphase Pharmaceuticals (TTPH)

Perilous Reversal Stock: Tetraphase Pharmaceuticals (TTPH)

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "perilous reversal" (up big yesterday but down big today) candidate

Tetraphase Pharmaceuticals (TTPH) Reaches New Lifetime High Today

Tetraphase Pharmaceuticals (TTPH) Reaches New Lifetime High Today

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Announces Positive Top-line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Announces Positive Top-line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-abdominal Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive...

Tetraphase Pharmaceuticals Added To NASDAQ Biotechnology Index

Tetraphase Pharmaceuticals Added To NASDAQ Biotechnology Index

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, today announced...

Tetraphase Pharmaceuticals To Present At The Oppenheimer 25th Annual Healthcare Conference

Tetraphase Pharmaceuticals To Present At The Oppenheimer 25th Annual Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic ...

New Lifetime High Reached: Tetraphase Pharmaceuticals (TTPH)

New Lifetime High Reached: Tetraphase Pharmaceuticals (TTPH)

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a new lifetime high candidate

Tetraphase Pharmaceuticals (TTPH) Is Today's Perilous Reversal Stock

Tetraphase Pharmaceuticals (TTPH) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "perilous reversal" (up big yesterday but down big today) candidate

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Participate In Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic ...

Tetraphase Pharmaceuticals Reports Third-Quarter 2014 Financial Results

Tetraphase Pharmaceuticals Reports Third-Quarter 2014 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operating highlights for the third quarter ended September 30, 2014.

First Week of December 20th Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of December 20th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the December 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTPH options chain for the new December 20th contracts and identified one put and one call contract of particular interest.

Tetraphase Pharmaceuticals Announces Closing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Closing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the closing of its underwritten public offering of 4,542,500 shares of common stock at an offering price of $19.

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a "perilous reversal" (up big yesterday but down big today) candidate

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Tetraphase Pharmaceuticals (TTPH) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Tetraphase Pharmaceuticals (TTPH) as a pre-market mover with heavy volume candidate

Tetraphase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of an underwritten public offering of 3,950,000 shares of common stock for a public offering price of $19.

TheStreet Quant Rating: D (Sell)